Skip to main content
Publications
Taylor MH, Leboulleux S, Panaseykin Y, Konda B, de La Fouchardiere C, Hughes BGM, Gianoukakis AG, Park YJ, Romanov I, Krzyzanowska MK, Garbinsky D, Sherif B, Pan JJ, Binder TA, Sauter N, Xie R, Brose MS. Health-related quality-of-life analyses from a multicenter, randomized, double-blind phase 2 study of patients with differentiated thyroid cancer treated with lenvatinib 18 or 24 mg/day. Cancer Med. 2023 Feb;12(4):4332-42. doi: 10.1002/cam4.5308
Mease P, Gladman D, Davenport E, Zhou X, Guerette B, Teng L, Kaura S, Nash P. Improvements in work productivity with up to 104 weeks of apremilast monotherapy: results from a phase 3b, randomized, controlled study in biologic-naïve subjects with active psoriatic arthritis. Poster presented at the 37th Scandinavian Congress of Rheumatology; September 5, 2018. Helsinki, Finland. [abstract] Scand J Rheumatol. 2018 Sep 5; 47(Suppl 129):34-5. Previously presented at the 2017 ACR/ARHP Annual Meeting.
Boccia S, Rothman KJ, Panic N, Flacco ME, Rosso A, Pastorino R, Manzoli L, La Vecchia C, Villari P, Boffetta P, Ricciardi W, Ioannidis JP. Registration practices for observational studies on ClinicalTrials.gov indicated low adherence. J Clin Epidemiol. 2016 Feb;70:176-82. doi: 10.1016/j.jclinepi.2015.09.009
Lupo PJ, Danysh HE, Plon SE, Curtin K, Malkin D, Hettmer S, Hawkins DS, Skapek SX, Spector LG, Papworth K, Melin B, Erhardt EB, Grufferman S, Schiffman JD. Family history of cancer and childhood rhabdomyosarcoma: a report from the Children's Oncology Group and the Utah Population Database. Cancer Med. 2015 May;4(5):781-90. doi: 10.1002/cam4.448